打开APP

GE医疗与CDI签署iPSC细胞检测产品及模型许可协议

  1. CDI
  2. GE医疗

来源:生物谷 2013-01-04 09:59

2012年12月29日讯 /生物谷BIOON/ --GE医疗集团(GE Healthcare)宣布,已与细胞动力学公司(Cellular Dynamics International,CDI)签署了一项许可协议,开发新的细胞分析检测产品。根据协议,GE医疗授权CDI开发、生产、销售源于诱导性多能干细胞的细胞分析检测产品及模型,这些产品及模型可用于药物发现及毒性筛选。

2012年12月29日讯 /生物谷BIOON/ --GE医疗集团(GE Healthcare)宣布,已与细胞动力学公司(Cellular Dynamics International,CDI)签署了一项许可协议,开发新的细胞分析检测产品。根据协议,GE医疗授权CDI开发、生产、销售源于诱导性多能干细胞的细胞分析检测产品及模型,这些产品及模型可用于药物发现及毒性筛选。(生物谷bioon.com)

英文原文:

GE Healthcare has announced a new sublicensing agreement with Cellular Dynamics International (CDI) pertaining to the development of new cellular assays.

Under the terms of the deal, GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from induced pluripotent stem cells for use in drug discovery and toxicity screening.

It follows on from a recent intellectual property rights agreement between GE Healthcare and assay developer Geron and strengthens the company's efforts to accelerate the creation of new pharmaceutical products.

CDI is responsible for the sale of iCell cardiomyocytes, neurons, endothelial cells and hepatocytes, as well as the custom cell manufacturing service MyCell.

Dr Amr Abid, general manager for cell technologies at GE Healthcare Life Sciences, said: "It is important that stem cell-based assays are available to researchers so that progress can be made in drug discovery; clarity and freedom to operate is fundamental to advancing the use of such assays."

This also comes after GE Healthcare agreed to assist Merck Sharp and Dohme in carrying out a clinical trial of a new Alzheimer's disease drug earlier this month.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->